Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
The Laryngoscope|December 30, 2020
Transoral Robotic Retropharyngeal Lymph Node Dissection in Nasopharyngeal Carcinoma With Retropharyngeal Lymph Node RecurrenceXi Ding, Qing-Guang Lin, Xiong Zou, et al.
Head & Neck|September 28, 2020
Transcervical endoscopic retropharyngeal lymph node (RPLN) dissection in nasopharyngeal carcinoma with RPLN recurrenceYou-Ping Liu, Shun-Lan Wang, Xiong Zou, et al.
Eclinicalmedicine|July 7, 2023
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyXi Ding, Yi-Jun Hua, Xiong Zou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2023
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II StudyXi Ding, Wei-Jing Zhang, Rui You, et al.
Therapeutic Advances in Medical Oncology|July 21, 2022
Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective studyMeng-Xia Zhang, Ting Liu, Rui You, et al.
Cell Reports. Medicine|October 16, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinomaXiong Zou, Xi Ding, Zheng-Kai Feng, et al.
Cell Reports. Medicine|November 11, 2023
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trialSi-Yuan Chen, Xiao-Tong Duan, Hui-Feng Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2025
Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinomaSi-Yuan Chen, Xiao-Tong Duan, Rui-Ling Xie, et al.
NEJM Evidence|April 22, 2025
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal CarcinomaPei-Yu Huang, Xu-Yin Chen, Xi Ding, et al.
BMJ (Clinical Research Ed.)|February 10, 2026
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trialRui You, Gui-Qiong Xu, Xi Ding, et al.
Pageof 11